GlassScriptPhysician profile
Lawrence L Kohn
NPI 1407838519
$847.27
in general payments reported to CMS, 2019-2025
20 companies · $16.86 in 2025
The $16.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.69 · 2020: $30.93 · 2021: $14.81 · 2023: $189 · 2024: $583 · 2025: $16.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127.05 | 2023-2024 | Rybelsus, Ozempic, Tresiba |
| Corcept Therapeutics | $92.56 | 2024 | Korlym |
| Abbvie INC. | $66.69 | 2023-2024 | |
| Eisai INC. | $61.22 | 2024 | |
| Janssen Pharmaceuticals, INC | $56.73 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $50.34 | 2021-2024 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $45.08 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Exact Sciences Corporation | $44.99 | 2023-2024 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $43.62 | 2019-2020 | |
| Abbott Laboratories | $41.77 | 2024 | Freestyle Libre 3 |
| Amgen INC. | $38.68 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $31.86 | 2024 | |
| Lilly USA, LLC | $28.10 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Dexcom, INC. | $23.96 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2024 | Synjardy, Jardiance, Tradjenta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.86 | 2025 | Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $15.88 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $15.16 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $14.81 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.49 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.